PMID: 8610638Apr 1, 1996Paper

Survival of patients with neuroblastoma treated with 125-I MIBG

American Journal of Clinical Oncology
J C SissonS A Zempel

Abstract

Recurrent or persistent neuroblastoma in stages III and IV is usually fatal despite modern therapies. Metaiodobenzylguanidine labeled with 131-I (131-I MIBG) concentrates in most neuroblastoma and when given in doses that impart therapeutic radiation, has produced remissions in patients with these tumors. However, success with 131-I MIBG has been limited. The physical characteristics of radiation imparted by 125-I MIBG theoretically could overcome some of the limitations that restrain the therapeutic effects of 131-I MIBG in patients with neuroblastoma. Thereby, 125-I MIBG may offer advantages over 131-I MIBG in the treatment of neuroblastoma. Ten children who manifested persistent/recurrent stage III or IV neuroblastoma were given 8.3 to 30.1 GBq or 224 to 814 mCi of 125-I MIBG in a phase I-II trial. Five of the patients had progression-free survivals > 1 year (continuing in three patients), and four of these subjects are surviving 17 to 52 months after treatment with 125-I MIBG. With appropriate doses of 125-I MIBG, life-threatening toxicity can be avoided. Thus, survivals after 125-I MIBG appear to be as long or longer than those historically observed following other treatments for patients similarly afflicted with refractor...Continue Reading

References

Jun 1, 1992·American Journal of Clinical Oncology·R J HutchinsonJ W Johnson
Mar 1, 1988·International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine·D E Charlton, J L Humm
Oct 31, 1985·The New England Journal of Medicine·R C SeegerD Hammond
Jan 1, 1994·European Journal of Nuclear Medicine·J C SissonD P Normolle
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R LadensteinT Philip
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R LadensteinT Philip

❮ Previous
Next ❯

Citations

Jun 2, 1998·International Journal of Radiation Oncology, Biology, Physics·W H RoaL I Wiebe
Jul 23, 1998·Auris, Nasus, Larynx·K J KairemoH A Ramsay
Oct 6, 1999·Journal of the American College of Surgeons·J L Grosfeld
Dec 4, 2008·Nuclear Medicine and Biology·Steven G DuBois, Katherine K Matthay
Feb 27, 2003·Pediatric Transplantation·Eneida R Nemecek, Dana C Matthews
Apr 6, 2012·Seminars in Nuclear Medicine·James C Sisson, Gregory A Yanik
Feb 13, 2003·Pediatric Clinics of North America·Carla B Golden, James H Feusner
Apr 16, 2015·TheScientificWorldJournal·Daiki Kayano, Seigo Kinuya
Feb 2, 2010·Seminars in Nuclear Medicine·Frank Grünwald, Samer Ezziddin
Apr 12, 2018·Cancer Biotherapy & Radiopharmaceuticals·Joseph GrudzinskiBryan Bednarz
Aug 10, 2006·European Journal of Nuclear Medicine and Molecular Imaging·Franz BucheggerAngelika Bischof Delaloye

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.